Beroni Group Limited Published Article on the FEBS Journal

Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, today announced that its article entitled "Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies" has been accepted for publication and undergone full review in the FEBS Journal.

The FEBS Journal is an international peer-reviewed non-profit society journal devoted to publishing high-quality papers reporting significant advances in the molecular life sciences.

The published article is related to the scientific findings derived from Beroni's current research of the development of a medical solution using single-domain antibodies (sdAbs) for the SARS-CoV-2 coronavirus. The Company has identified 2 crystal structures of nucleocapsid protein C-terminal domain. Nucleocapsid protein is a major structural protein of SARS-CoV-2 and plays an important role in viral RNA packing, replication, assembly, and infection. Through screening a sdAbs library, the scientific team has identified four sdAbs targeting different regions of nucleocapsid protein with high affinities that have future potential to be used in viral detection and therapeutic purposes.

"We are delighted to progress further in our coronavirus research program and to publish our new findings in the FEBS journal. The Company plans to carry out a series of experiments to gradually transform the results into clinical trials and find a new way for the diagnosis and treatment of the new coronavirus. Beroni hopes our efforts can contribute to the basic understanding of the SARS-CoV-2 coronavirus and the global development of antiviral drugs." said Jacky Zhang, Chairman and CEO of Beroni Group.

The full article can be viewed at:
https://www.abnnewswire.net/lnk/33G6S6JT



About Beroni Group Limited:  

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.



Source:
Beroni Group Limited



Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

News Provided by ABN Newswire via QuoteMedia

The Conversation (0)
B2Gold Corp.

B2Gold Corp.

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other significant assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into a global market. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; other mineral properties; and corporate and other. It generates maximum revenue from the Fekola mine segment in Mali.

Aurum Resources (ASX:AUE)

Aurum Resources


Keep reading...Show less
David Erfle, gold bars.

David Erfle: Silver Staging "Powerful" Breakout; Plus Gold Stocks and Copper Squeeze

David Erfle, editor and founder of Junior Miner Junky, shares his short-term outlook for gold, saying it could see a healthy test of US$3,200 per ounce — or even US$2,950 to US$3,000.

Erfle also shares his thoughts on what's coming for silver and copper prices.

Keep reading...Show less

Latest Press Releases

Related News

×